SOLIGENIX, INC. Sale of Stock, Consideration Received on Transaction
SOLIGENIX, INC. (SNGX) reported Sale of Stock, Consideration Received on Transaction of $6.30 million for the 1-month period ending 2019-11-07, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2019-11-12
- 2019-11-07: Sale of Stock, Consideration Received on Transaction 1 month $6.30M.
- 2019-08-08: Sale of Stock, Consideration Received on Transaction 0 month $6.60M.
| Period end | Sale of Stock, Consideration Received on Transaction 0 month | Sale of Stock, Consideration Received on Transaction 1 month |
|---|---|---|
| 2019-11-07 | $6.30M 10-Q · filed 2019-11-12 | |
| 2019-08-08 | $6.60M 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |